1r47 › Citations

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.

Garman SC, Garboczi DN
J Mol Biol 337 319-35 (2004)
Cited: 198 times
EuropePMC logo PMID: 15003450

Abstract

Fabry disease is an X-linked lysosomal storage disease afflicting 1 in 40,000 males with chronic pain, vascular degeneration, cardiac impairment, and other symptoms. Deficiency in the lysosomal enzyme alpha-galactosidase (alpha-GAL) causes an accumulation of its substrate, which ultimately leads to Fabry disease symptoms. Here, we present the structure of the human alpha-GAL glycoprotein determined by X-ray crystallography. The structure is a homodimer with each monomer containing a (beta/alpha)8 domain with the active site and an antiparallel beta domain. N-linked carbohydrate appears at six sites in the glycoprotein dimer, revealing the basis for lysosomal transport via the mannose-6-phosphate receptor. To understand how the enzyme cleaves galactose from glycoproteins and glycolipids, we also determined the structure of the complex of alpha-GAL with its catalytic product. The catalytic mechanism of the enzyme is revealed by the location of two aspartic acid residues (D170 and D231), which act as a nucleophile and an acid/base, respectively. As a point mutation in alpha-GAL can lead to Fabry disease, we have catalogued and plotted the locations of 245 missense and nonsense mutations in the three-dimensional structure. The structure of human alpha-GAL brings Fabry disease into the realm of molecular diseases, where insights into the structural basis of the disease phenotypes might help guide the clinical treatment of patients.

Articles - 1r47 mentioned but not cited (11)

  1. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Lieberman RL, D'aquino JA, Ringe D, Petsko GA. Biochemistry 48 4816-4827 (2009)
  2. A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP, Schiffmann R, Boudes P, Lockhart DJ, Valenzano KJ, Benjamin ER. Hum Mutat 32 965-977 (2011)
  3. A beta-l-Arabinopyranosidase from Streptomyces avermitilis is a novel member of glycoside hydrolase family 27. Ichinose H, Fujimoto Z, Honda M, Harazono K, Nishimoto Y, Uzura A, Kaneko S. J Biol Chem 284 25097-25106 (2009)
  4. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, Togawa T, Chiba Y, Jigami Y, Ohno K, Fukushige T, Kanekura T, Itoh K, Ohashi T, Sakuraba H. Am J Hum Genet 85 569-580 (2009)
  5. High throughput screening for inhibitors of alpha-galactosidase. Motabar O, Liu K, Southall N, Marugan JJ, Goldin E, Sidransky E, Zheng W. Curr Chem Genomics 4 67-73 (2010)
  6. Characterization of gana-1, a Caenorhabditis elegans gene encoding a single ortholog of vertebrate alpha-galactosidase and alpha-N-acetylgalactosaminidase. Hujová J, Sikora J, Dobrovolný R, Poupetová H, Ledvinová J, Kostrouchová M, Hrebícek M. BMC Cell Biol 6 5 (2005)
  7. Novel propanolamine derivatives attached to 2-metoxifenol moiety: Synthesis, characterization, biological properties, and molecular docking studies. Genc Bilgicli H, Ergon D, Taslimi P, Tüzün B, Akyazı Kuru İ, Zengin M, Gülçin İ. Bioorg Chem 101 103969 (2020)
  8. Automated identification of protein-ligand interaction features using Inductive Logic Programming: a hexose binding case study. A Santos JC, Nassif H, Page D, Muggleton SH, E Sternberg MJ. BMC Bioinformatics 13 162 (2012)
  9. Carboxyl-terminal truncations alter the activity of the human α-galactosidase A. Meghdari M, Gao N, Abdullahi A, Stokes E, Calhoun DH. PLoS One 10 e0118341 (2015)
  10. An Inductive Logic Programming Approach to Validate Hexose Binding Biochemical Knowledge. Nassif H, Al-Ali H, Khuri S, Keirouz W, Page D. Inductive Log Program 5989 149-165 (2010)
  11. In vitro inhibitory effects of some acetophenone derivatives on some metabolic enzymes and molecular docking. Taslimi P. Arch Pharm (Weinheim) 353 e2000210 (2020)


Reviews citing this publication (35)

  1. Fabry disease. Germain DP. Orphanet J Rare Dis 5 30 (2010)
  2. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Genet Med 8 539-548 (2006)
  3. Fabry disease. Schiffmann R. Pharmacol Ther 122 65-77 (2009)
  4. Fabry disease: a review of current management strategies. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP. QJM 103 641-659 (2010)
  5. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. Fan JQ, Ishii S. FEBS J 274 4962-4971 (2007)
  6. Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience. Tekoah Y, Shulman A, Kizhner T, Ruderfer I, Fux L, Nataf Y, Bartfeld D, Ariel T, Gingis-Velitski S, Hanania U, Shaaltiel Y. Plant Biotechnol J 13 1199-1208 (2015)
  7. Anderson-Fabry disease and the heart. O'Mahony C, Elliott P. Prog Cardiovasc Dis 52 326-335 (2010)
  8. Pharmacological chaperoning: a primer on mechanism and pharmacology. Leidenheimer NJ, Ryder KG. Pharmacol Res 83 10-19 (2014)
  9. Hereditary cerebral small vessel diseases: a review. Federico A, Di Donato I, Bianchi S, Di Palma C, Taglia I, Dotti MT. J Neurol Sci 322 25-30 (2012)
  10. Progress in the understanding and treatment of Fabry disease. Miller JJ, Kanack AJ, Dahms NM. Biochim Biophys Acta Gen Subj 1864 129437 (2020)
  11. Fabry disease, enzyme replacement therapy and the significance of antibody responses. Deegan PB. J Inherit Metab Dis 35 227-243 (2012)
  12. Neurological manifestations in Fabry's disease. Møller AT, Jensen TS. Nat Clin Pract Neurol 3 95-106 (2007)
  13. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Schaefer E, Mehta A, Gal A. Acta Paediatr Suppl 94 87-92; discussion 79 (2005)
  14. Monogenic causes of stroke: now and the future. Tan RY, Markus HS. J Neurol 262 2601-2616 (2015)
  15. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Biomolecules 11 271 (2021)
  16. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises. Mohamed FE, Al-Gazali L, Al-Jasmi F, Ali BR. Front Pharmacol 8 448 (2017)
  17. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Warnock DG. Curr Opin Nephrol Hypertens 14 87-95 (2005)
  18. Pharmacological chaperone therapy for lysosomal storage diseases. Parenti G, Moracci M, Fecarotta S, Andria G. Future Med Chem 6 1031-1045 (2014)
  19. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders. Ryckman AE, Brockhausen I, Walia JS. Int J Mol Sci 21 E6881 (2020)
  20. Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations. Oliveira JP, Ferreira S. Appl Clin Genet 12 35-50 (2019)
  21. Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Tran ML, Génisson Y, Ballereau S, Dehoux C. Molecules 25 E3145 (2020)
  22. Single gene disorders causing ischaemic stroke. Razvi SS, Bone I. J Neurol 253 685-700 (2006)
  23. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Viggiano E, Politano L. Int J Mol Sci 22 7663 (2021)
  24. Structural aspects of therapeutic enzymes to treat metabolic disorders. Kang TS, Stevens RC. Hum Mutat 30 1591-1610 (2009)
  25. Diagnosis and management of kidney involvement in Fabry disease. Warnock DG, West ML. Adv Chronic Kidney Dis 13 138-147 (2006)
  26. Ischemic Stroke Genetics: What Is New and How to Apply It in Clinical Practice? Ekkert A, Šliachtenko A, Grigaitė J, Burnytė B, Utkus A, Jatužis D. Genes (Basel) 13 48 (2021)
  27. Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging. Fellgiebel A, Albrecht J, Dellani PR, Schermuly I, Stoeter P, Müller MJ. Acta Paediatr 96 33-36 (2007)
  28. Clinical Insights Into Heritable Cardiomyopathies. Martinez HR, Beasley GS, Miller N, Goldberg JF, Jefferies JL. Front Genet 12 663450 (2021)
  29. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease. Modrego A, Amaranto M, Godino A, Mendoza R, Barra JL, Corchero JL. Int J Mol Sci 22 6518 (2021)
  30. Hooked on α-d-galactosidases: from biomedicine to enzymatic synthesis. Bakunina IY, Balabanova LA, Pennacchio A, Trincone A. Crit Rev Biotechnol 36 233-245 (2016)
  31. Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches. Lombardi S, Testa MF, Pinotti M, Branchini A. Int J Mol Sci 21 E9449 (2020)
  32. Fabry Nephropathy. Colpart P, Félix S. Arch Pathol Lab Med 141 1127-1131 (2017)
  33. Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease. Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Löscher W, Grisold W. Acta Neurol Scand 136 558-569 (2017)
  34. An Overview of Molecular Mechanisms in Fabry Disease. Amodio F, Caiazza M, Monda E, Rubino M, Capodicasa L, Chiosi F, Simonelli V, Dongiglio F, Fimiani F, Pepe N, Chimenti C, Calabrò P, Limongelli G. Biomolecules 12 1460 (2022)
  35. Fabry's disease: an example of cardiorenal syndrome type 5. Sharma A, Sartori M, Zaragoza JJ, Villa G, Lu R, Faggiana E, Brocca A, Di Lullo L, Feriozzi S, Ronco C. Heart Fail Rev 20 689-708 (2015)

Articles citing this publication (152)

  1. High incidence of later-onset fabry disease revealed by newborn screening. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. Am J Hum Genet 79 31-40 (2006)
  2. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. Benjamin ER, Flanagan JJ, Schilling A, Chang HH, Agarwal L, Katz E, Wu X, Pine C, Wustman B, Desnick RJ, Lockhart DJ, Valenzano KJ. J Inherit Metab Dis 32 424-440 (2009)
  3. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Hum Genomics 2 297-309 (2006)
  4. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, Rolfs A. PLoS Genet 9 e1003632 (2013)
  5. CNS manifestations of Fabry's disease. Fellgiebel A, Müller MJ, Ginsberg L. Lancet Neurol 5 791-795 (2006)
  6. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M. J Mol Med (Berl) 83 647-654 (2005)
  7. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ. Biochem J 406 285-295 (2007)
  8. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AA, Leitão A, Gabriel JP, Calado S, Oliveira JP, Ferro JM, PORTuguese Young STROKE Investigators. Stroke 41 431-436 (2010)
  9. Structure of the Sulfolobus solfataricus alpha-glucosidase: implications for domain conservation and substrate recognition in GH31. Ernst HA, Lo Leggio L, Willemoës M, Leonard G, Blum P, Larsen S. J Mol Biol 358 1106-1124 (2006)
  10. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Bénichou B, Goyal S, Sung C, Norfleet AM, O'Brien F. Mol Genet Metab 96 4-12 (2009)
  11. Is globotriaosylceramide a useful biomarker in Fabry disease? Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B. Acta Paediatr Suppl 94 51-4; discussion 37-8 (2005)
  12. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB, FOS Investigators. Br J Dermatol 157 331-337 (2007)
  13. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, West M, Wijatyk A, Giugliani R, Fabry Outcome Survey Study Group. Mol Genet Metab Rep 3 21-27 (2015)
  14. Catalytic mechanism of human alpha-galactosidase. Guce AI, Clark NE, Salgado EN, Ivanen DR, Kulminskaya AA, Brumer H, Garman SC. J Biol Chem 285 3625-3632 (2010)
  15. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JT, Drouin R. Mol Genet Metab 93 331-340 (2008)
  16. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cortés M, Gallegos-Villalobos Á, Garcia D, García-Robles JA, Egido J, Gutiérrez-Rivas E, Herrero JA, Mas S, Oancea R, Péres P, Salazar-Martín LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP. Mol Genet Metab 114 248-258 (2015)
  17. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. Gal A, Hughes DA, Winchester B. J Inherit Metab Dis 34 509-514 (2011)
  18. The molecular basis of pharmacological chaperoning in human α-galactosidase. Guce AI, Clark NE, Rogich JJ, Garman SC. Chem Biol 18 1521-1526 (2011)
  19. Outcomes of patients treated through the Canadian Fabry disease initiative. Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML, CFDI investigators. Mol Genet Metab 111 499-506 (2014)
  20. Crystal structure of α-galactosidase from Lactobacillus acidophilus NCFM: insight into tetramer formation and substrate binding. Fredslund F, Hachem MA, Larsen RJ, Sørensen PG, Coutinho PM, Lo Leggio L, Svensson B. J Mol Biol 412 466-480 (2011)
  21. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, Choe KH, Kim WH, Yang SH, Yoo HW. J Hum Genet 55 512-517 (2010)
  22. Neuropathic pain in a Fabry disease rat model. Miller JJ, Aoki K, Moehring F, Murphy CA, O'Hara CL, Tiemeyer M, Stucky CL, Dahms NM. JCI Insight 3 99171 (2018)
  23. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C, Liang SB, Murray GJ, Brady RO, Medin JA. Gene Ther 14 256-265 (2007)
  24. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H. Hum Genet 117 317-328 (2005)
  25. Functional studies of new GLA gene mutations leading to conformational Fabry disease. Filoni C, Caciotti A, Carraresi L, Cavicchi C, Parini R, Antuzzi D, Zampetti A, Feriozzi S, Poisetti P, Garman SC, Guerrini R, Zammarchi E, Donati MA, Morrone A. Biochim Biophys Acta 1802 247-252 (2010)
  26. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R, Brady RO, Murray GJ. Pharmacogenet Genomics 18 773-780 (2008)
  27. The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases. Clark NE, Garman SC. J Mol Biol 393 435-447 (2009)
  28. Arrhythmias in Fabry cardiomyopathy. Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, Plumb VJ, Tallaj JA. Clin Cardiol 35 738-740 (2012)
  29. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Boutin M, Gagnon R, Lavoie P, Auray-Blais C. Clin Chim Acta 414 273-280 (2012)
  30. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P. Nephron Clin Pract 101 c33-8 (2005)
  31. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. Seydelmann N, Liu D, Krämer J, Drechsler C, Hu K, Nordbeck P, Schneider A, Störk S, Bijnens B, Ertl G, Wanner C, Weidemann F. J Am Heart Assoc 5 e002839 (2016)
  32. Identification of a novel alpha-galactosidase from the hyperthermophilic archaeon Sulfolobus solfataricus. Brouns SJ, Smits N, Wu H, Snijders AP, Wright PC, de Vos WM, van der Oost J. J Bacteriol 188 2392-2399 (2006)
  33. Pharmacological chaperone therapy for Fabry disease. Ishii S. Proc Jpn Acad Ser B Phys Biol Sci 88 18-30 (2012)
  34. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency. Higaki K, Li L, Bahrudin U, Okuzawa S, Takamuram A, Yamamoto K, Adachi K, Paraguison RC, Takai T, Ikehata H, Tominaga L, Hisatome I, Iida M, Ogawa S, Matsuda J, Ninomiya H, Sakakibara Y, Ohno K, Suzuki Y, Nanba E. Hum Mutat 32 843-852 (2011)
  35. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. Andreotti G, Guarracino MR, Cammisa M, Correra A, Cubellis MV. Orphanet J Rare Dis 5 36 (2010)
  36. A novel alpha-galactosidase from Bifidobacterium bifidum with transgalactosylating properties: gene molecular cloning and heterologous expression. Goulas T, Goulas A, Tzortzis G, Gibson GR. Appl Microbiol Biotechnol 82 471-477 (2009)
  37. Chemoenzymatic Synthesis of a Phosphorylated Glycoprotein. Priyanka P, Parsons TB, Miller A, Platt FM, Fairbanks AJ. Angew Chem Int Ed Engl 55 5058-5061 (2016)
  38. Structure-function relationships in alpha-galactosidase A. Garman SC. Acta Paediatr 96 6-16 (2007)
  39. The molecular mechanism of thermostable α-galactosidases AgaA and AgaB explained by x-ray crystallography and mutational studies. Merceron R, Foucault M, Haser R, Mattes R, Watzlawick H, Gouet P. J Biol Chem 287 39642-39652 (2012)
  40. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K, Couceiro J, Van Durme J, Schymkowitz J, Rousseau F. J Biol Chem 287 28386-28397 (2012)
  41. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Sugawara K, Tajima Y, Kawashima I, Tsukimura T, Saito S, Ohno K, Iwamoto K, Kobayashi T, Itoh K, Sakuraba H. Mol Genet Metab 96 233-238 (2009)
  42. α-Galactosidase/sucrose kinase (AgaSK), a novel bifunctional enzyme from the human microbiome coupling galactosidase and kinase activities. Bruel L, Sulzenbacher G, Cervera Tison M, Pujol A, Nicoletti C, Perrier J, Galinier A, Ropartz D, Fons M, Pompeo F, Giardina T. J Biol Chem 286 40814-40823 (2011)
  43. Pharmacological chaperones for human α-N-acetylgalactosaminidase. Clark NE, Metcalf MC, Best D, Fleet GW, Garman SC. Proc Natl Acad Sci U S A 109 17400-17405 (2012)
  44. Structural analysis of Saccharomyces cerevisiae alpha-galactosidase and its complexes with natural substrates reveals new insights into substrate specificity of GH27 glycosidases. Fernández-Leiro R, Pereira-Rodríguez A, Cerdán ME, Becerra M, Sanz-Aparicio J. J Biol Chem 285 28020-28033 (2010)
  45. Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, Xu Y, Ni L, Yu X, Chen X, Zhang W, Yang L, Li X, Xu J, Chen N. PLoS One 11 e0161330 (2016)
  46. Structural characterization of mutant alpha-galactosidases causing Fabry disease. Sugawara K, Ohno K, Saito S, Sakuraba H. J Hum Genet 53 812-824 (2008)
  47. A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C. Lieberman RL. Enzyme Res 2011 973231 (2011)
  48. Novel tools for extraction and validation of disease-related mutations applied to Fabry disease. Kuipers R, van den Bergh T, Joosten HJ, Lekanne dit Deprez RH, Mannens MM, Schaap PJ. Hum Mutat 31 1026-1032 (2010)
  49. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Cabrera I, Abasolo I, Corchero JL, Elizondo E, Gil PR, Moreno E, Faraudo J, Sala S, Bueno D, González-Mira E, Rivas M, Melgarejo M, Pulido D, Albericio F, Royo M, Villaverde A, García-Parajo MF, Schwartz S, Ventosa N, Veciana J. Adv Healthc Mater 5 829-840 (2016)
  50. A novel protease-resistant alpha-galactosidase with high hydrolytic activity from Gibberella sp. F75: gene cloning, expression, and enzymatic characterization. Cao Y, Wang Y, Meng K, Bai Y, Shi P, Luo H, Yang P, Zhou Z, Zhang Z, Yao B. Appl Microbiol Biotechnol 83 875-884 (2009)
  51. Increasing the transglycosylation activity of alpha-galactosidase from Bifidobacterium adolescentis DSM 20083 by site-directed mutagenesis. Hinz SW, Doeswijk-Voragen CH, Schipperus R, van den Broek LA, Vincken JP, Voragen AG. Biotechnol Bioeng 93 122-131 (2006)
  52. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, Winchester B. Eur J Pediatr 163 595-603 (2004)
  53. UniProt genomic mapping for deciphering functional effects of missense variants. McGarvey PB, Nightingale A, Luo J, Huang H, Martin MJ, Wu C, UniProt Consortium. Hum Mutat 40 694-705 (2019)
  54. Fabry disease in a Japanese population-molecular and biochemical characteristics. Sakuraba H, Tsukimura T, Togawa T, Tanaka T, Ohtsuka T, Sato A, Shiga T, Saito S, Ohno K. Mol Genet Metab Rep 17 73-79 (2018)
  55. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Ferri L, Guido C, la Marca G, Malvagia S, Cavicchi C, Fiumara A, Barone R, Parini R, Antuzzi D, Feliciani C, Zampetti A, Manna R, Giglio S, Della Valle CM, Wu X, Valenzano KJ, Benjamin R, Donati MA, Guerrini R, Genuardi M, Morrone A. Clin Genet 81 224-233 (2012)
  56. Macular Impairment in Fabry Disease: A Morpho-functional Assessment by Swept-Source OCT Angiography and Focal Electroretinography. Minnella AM, Barbano L, Verrecchia E, Martelli F, Pagliei V, Gambini G, Placidi G, Falsini B, Caporossi A, Manna R. Invest Ophthalmol Vis Sci 60 2667-2675 (2019)
  57. Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. Riera C, Lois S, Domínguez C, Fernandez-Cadenas I, Montaner J, Rodríguez-Sureda V, de la Cruz X. Proteins 83 91-104 (2015)
  58. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry. Krüger R, Tholey A, Jakoby T, Vogelsberger R, Mönnikes R, Rossmann H, Beck M, Lackner KJ. J Chromatogr B Analyt Technol Biomed Life Sci 883-884 128-135 (2012)
  59. Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Unzueta U, Vázquez F, Accardi G, Mendoza R, Toledo-Rubio V, Giuliani M, Sannino F, Parrilli E, Abasolo I, Schwartz S, Tutino ML, Villaverde A, Corchero JL, Ferrer-Miralles N. Appl Microbiol Biotechnol 99 5863-5874 (2015)
  60. Determination of globotriaosylceramide in plasma and urine by mass spectrometry. Krüger R, Bruns K, Grünhage S, Rossmann H, Reinke J, Beck M, Lackner KJ. Clin Chem Lab Med 48 189-198 (2010)
  61. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro. Brogden G, Shammas H, Maalouf K, Naim SL, Wetzel G, Amiri M, von Köckritz-Blickwede M, Das AM, Naim HY. Biosci Rep 37 BSR20160402 (2017)
  62. Crystal structure of the catalytic domain of Drosophila beta1,4-Galactosyltransferase-7. Ramakrishnan B, Qasba PK. J Biol Chem 285 15619-15626 (2010)
  63. GH97 is a new family of glycoside hydrolases, which is related to the alpha-galactosidase superfamily. Naumoff DG. BMC Genomics 6 112 (2005)
  64. Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases. Tomasic IB, Metcalf MC, Guce AI, Clark NE, Garman SC. J Biol Chem 285 21560-21566 (2010)
  65. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Ferreira S, Auray-Blais C, Boutin M, Lavoie P, Nunes JP, Martins E, Garman S, Oliveira JP. Clin Chim Acta 447 96-104 (2015)
  66. A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease. Li P, Zhang L, Zhao N, Xiong Q, Zhou YA, Wu C, Xiao H. Front Genet 10 60 (2019)
  67. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. Pisani A, Imbriaco M, Zizzo C, Albeggiani G, Colomba P, Alessandro R, Iemolo F, Duro G. BMC Cardiovasc Disord 12 39 (2012)
  68. A successful approach for the detection of Fabry patients in Argentina. Rozenfeld PA, Tarabuso A, Ebner R, Ramallo G, Fossati CA. Clin Genet 69 344-348 (2006)
  69. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Mol Genet Metab 114 268-273 (2015)
  70. Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations. Ferri L, Covello G, Caciotti A, Guerrini R, Denti MA, Morrone A. Mol Ther Nucleic Acids 5 e380 (2016)
  71. Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones. Monticelli M, Liguori L, Allocca M, Bosso A, Andreotti G, Lukas J, Monti MC, Morretta E, Cubellis MV, Hay Mele B. Int J Mol Sci 23 5105 (2022)
  72. Fabry disease: a new approach for the screening of females in high-risk groups. Pasqualim G, Simon L, Sperb-Ludwig F, Burin MG, Michelin-Tirelli K, Giugliani R, Matte U. Clin Biochem 47 657-662 (2014)
  73. Impact of cysteine variants on the structure, activity, and stability of recombinant human α-galactosidase A. Qiu H, Honey DM, Kingsbury JS, Park A, Boudanova E, Wei RR, Pan CQ, Edmunds T. Protein Sci 24 1401-1411 (2015)
  74. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy. Goker-Alpan O, Longo N, McDonald M, Shankar SP, Schiffmann R, Chang P, Shen Y, Pano A. Drug Des Devel Ther 10 1771-1781 (2016)
  75. Crystal Structure and Mutational Analysis of Isomalto-dextranase, a Member of Glycoside Hydrolase Family 27. Okazawa Y, Miyazaki T, Yokoi G, Ishizaki Y, Nishikawa A, Tonozuka T. J Biol Chem 290 26339-26349 (2015)
  76. De novo mutation in a male patient with Fabry disease: a case report. Iemolo F, Pizzo F, Albeggiani G, Zizzo C, Colomba P, Scalia S, Bartolotta C, Duro G. BMC Res Notes 7 11 (2014)
  77. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A. Drug Des Devel Ther 9 3435-3444 (2015)
  78. Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients. Rozenfeld PA, Croxatto O, Ebner R, Fossati CA. Clin Exp Ophthalmol 34 689-694 (2006)
  79. A new α-galactosidase from symbiotic Flavobacterium sp. TN17 reveals four residues essential for α-galactosidase activity of gastrointestinal bacteria. Zhou J, Shi P, Huang H, Cao Y, Meng K, Yang P, Zhang R, Chen X, Yao B. Appl Microbiol Biotechnol 88 1297-1309 (2010)
  80. Growth of Chitinophaga pinensis on Plant Cell Wall Glycans and Characterisation of a Glycoside Hydrolase Family 27 β-l-Arabinopyranosidase Implicated in Arabinogalactan Utilisation. McKee LS, Brumer H. PLoS One 10 e0139932 (2015)
  81. Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells. Corchero JL, Mendoza R, Lorenzo J, Rodríguez-Sureda V, Domínguez C, Vázquez E, Ferrer-Miralles N, Villaverde A. Biotechnol Prog 27 1206-1217 (2011)
  82. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. Sadasivan C, Chow JTY, Sheng B, Chan DKH, Fan Y, Choi PCL, Wong JKT, Tong MMB, Chan TN, Fung E, Kam KKH, Chan JYS, Chi WK, Paterson DI, Senaratne M, Brass N, Oudit GY, Lee APW. PLoS One 15 e0239675 (2020)
  83. Chicory: Understanding the Effects and Effectors of This Functional Food. Pouille CL, Ouaza S, Roels E, Behra J, Tourret M, Molinié R, Fontaine JX, Mathiron D, Gagneul D, Taminiau B, Daube G, Ravallec R, Rambaud C, Hilbert JL, Cudennec B, Lucau-Danila A. Nutrients 14 957 (2022)
  84. Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A. Saito S, Ohno K, Sakuraba H. PLoS One 8 e84267 (2013)
  85. Efficient and rapid purification of recombinant human alpha-galactosidase A by affinity column chromatography. Yasuda K, Chang HH, Wu HL, Ishii S, Fan JQ. Protein Expr Purif 37 499-506 (2004)
  86. Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars. Tsukimura T, Chiba Y, Ohno K, Saito S, Tajima Y, Sakuraba H. Mol Genet Metab 103 26-32 (2011)
  87. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease. Duro G, Musumeci MB, Colomba P, Zizzo C, Albeggiani G, Mastromarino V, Volpe M, Autore C. Gene 535 365-369 (2014)
  88. Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease. Tsukimura T, Nakano S, Togawa T, Tanaka T, Saito S, Ohno K, Shibasaki F, Sakuraba H. Mol Genet Metab Rep 1 288-298 (2014)
  89. Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants. Lombardi S, Ferrarese M, Marchi S, Pinton P, Pinotti M, Bernardi F, Branchini A. RNA Biol 17 254-263 (2020)
  90. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Rozenfeld PA, De Francesco NP, Borrajo GJ, Ceci R, Fossati CA. Clin Chim Acta 403 194-197 (2009)
  91. Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase. Cimmaruta C, Citro V, Andreotti G, Liguori L, Cubellis MV, Hay Mele B. BMC Bioinformatics 19 433 (2018)
  92. Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs. Colomba P, Zizzo C, Alessandro R, Cammarata G, Scalia S, Giordano A, Pieroni M, Sicurella L, Amico L, Burlina A, Duro G. Oncotarget 9 7758-7762 (2018)
  93. Late-onset Fabry disease associated with angiokeratoma of Fordyce and multiple cherry angiomas. Hogarth V, Dhoat S, Mehta AB, Orteu CH. Clin Exp Dermatol 36 506-508 (2011)
  94. Schistosoma mansoni α-N-acetylgalactosaminidase (SmNAGAL) regulates coordinated parasite movement and egg production. Hulme BJ, Geyer KK, Forde-Thomas JE, Padalino G, Phillips DW, Ittiprasert W, Karinshak SE, Mann VH, Chalmers IW, Brindley PJ, Hokke CH, Hoffmann KF. PLoS Pathog 18 e1009828 (2022)
  95. The α-galactosidase type A gene aglA from Aspergillus niger encodes a fully functional α-N-acetylgalactosaminidase. Kulik N, Weignerová L, Filipi T, Pompach P, Novák P, Mrázek H, Slámová K, Bezouska K, Kren V, Ettrich R. Glycobiology 20 1410-1419 (2010)
  96. Updates on smart polymeric carrier systems for protein delivery. El-Sherbiny I, Khalil I, Ali I, Yacoub M. Drug Dev Ind Pharm 43 1567-1583 (2017)
  97. Contribution of clinical screening to carrier detection in a large Chinese family with Fabry disease due to a novel alpha-galactosidase A gene deletion. Ro LS, Chen CM, Chang HS, Lyu RK, Wu YR, Hsu WC, Lee-Chen GJ. Eur J Neurol 14 493-497 (2007)
  98. Fabry's disease: otoneurologic findings in twelve members of one family. Vibert D, Blaser B, Ozdoba C, Häusler R. Ann Otol Rhinol Laryngol 115 412-418 (2006)
  99. Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. Nakamura G, Maruyama H, Ishii S, Shimotori M, Kameda S, Kono T, Miyazaki J, Kulkarni AB, Gejyo F. Mol Biotechnol 38 109-119 (2008)
  100. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey. Barman HA, Özcan S, Atıcı A, Özgökçe C, Öztürk A, Kafalı AE, Çakar NE, Tavşanlı ME, Küçük M, Şahin I, Okuyan E. Anatol J Cardiol 23 79-85 (2020)
  101. Screening of Fabry disease in patients with chronic kidney disease in Japan. Nagata A, Nasu M, Kaida Y, Nakayama Y, Kurokawa Y, Nakamura N, Shibata R, Hazama T, Tsukimura T, Togawa T, Saito S, Sakuraba H, Fukami K. Nephrol Dial Transplant 37 115-125 (2021)
  102. [Hearing loss in patients with Fabry disease]. Limberger A, Beck M, Delgado-Sanchez S, Keilmann A. HNO 55 185-189 (2007)
  103. Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants. Encarnação M, Coutinho MF, Silva L, Ribeiro D, Ouesleti S, Campos T, Santos H, Martins E, Cardoso MT, Vilarinho L, Alves S. Int J Mol Sci 21 E6355 (2020)
  104. Case Reports Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease. Limongelli G, Masarone D, Verrengia M, Gravino R, Salerno G, Castelletti S, Rubino M, Marrazzo T, Pisani A, Cecchi F, Elliott PM, Pacileo G. J Cardiovasc Echogr 28 120-123 (2018)
  105. Fabry disease: treatment and diagnosis. Rozenfeld PA. IUBMB Life 61 1043-1050 (2009)
  106. Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events. Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, Giugliani R. Mol Genet Metab Rep 14 31-35 (2018)
  107. Case Reports Novel GLA Mutation Promotes Intron Inclusion Leading to Fabry Disease. Varela P, Caldas MM, Pesquero JB. Front Genet 10 783 (2019)
  108. Novel sequence variants of the alpha-galactosidase A gene in patients with Fabry disease. Erdos M, Németh K, Tóth B, Constantin T, Rákóczi E, Ponyi A, Dajnoki A, Grubits J, Pintér I, Garzuly F, Hahn K, Bencsik K, Vécsei L, Fekete G, Maródi L. Mol Genet Metab 95 224-228 (2008)
  109. Structure-specificity relationships in Abp, a GH27 β-L-arabinopyranosidase from Geobacillus stearothermophilus T6. Lansky S, Salama R, Solomon HV, Feinberg H, Belrhali H, Shoham Y, Shoham G. Acta Crystallogr D Biol Crystallogr 70 2994-3012 (2014)
  110. The pathophysiology of Fabry disease. Olivera-González S, Josa-Laorden C, Torralba-Cabeza MA. Rev Clin Esp (Barc) 218 22-28 (2018)
  111. Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T). Ebrahim HY, Baker RJ, Mehta AB, Hughes DA. J Inherit Metab Dis 35 325-334 (2012)
  112. In Silico Analysis of Missense Mutations as a First Step in Functional Studies: Examples from Two Sphingolipidoses. Duarte AJ, Duarte AJ, Ribeiro D, Moreira L, Amaral O. Int J Mol Sci 19 E3409 (2018)
  113. Spiro-epoxyglycosides as Activity-Based Probes for Glycoside Hydrolase Family 99 Endomannosidase/Endomannanase. Schröder SP, Kallemeijn WW, Debets MF, Hansen T, Sobala LF, Hakki Z, Williams SJ, Beenakker TJM, Aerts JMFG, van der Marel GA, Codée JDC, Davies GJ, Overkleeft HS. Chemistry 24 9983-9992 (2018)
  114. X-chromosomal inactivation patterns in women with Fabry disease. Wagenhäuser L, Rickert V, Sommer C, Wanner C, Nordbeck P, Rost S, Üçeyler N. Mol Genet Genomic Med 10 e2029 (2022)
  115. An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy. Inagaki S, Migita M, Hayakawa M, Fujita A, Yoshida J, Ishizaki M, Kotani M, Sakuraba H, Shimada T, Murakami M, Fukunaga Y. J Nippon Med Sch 72 387-390 (2005)
  116. Clinical, histological and molecular characteristics of Mexican patients with Fabry disease and significant renal involvement. Ramos-Kuri M, Olvera D, Morales JJ, Rodriguez-Espino BA, Lara-Mejía A, De Los Ríos D, Obrador GT, Granados J, Correa-Rotter R. Arch Med Res 45 257-262 (2014)
  117. Crystallization and preliminary X-ray diffraction studies of two thermostable alpha-galactosidases from glycoside hydrolase family 36. Foucault M, Watzlawick H, Mattes R, Haser R, Gouet P. Acta Crystallogr Sect F Struct Biol Cryst Commun 62 100-103 (2006)
  118. Fabry disease and immunoglobulin A nephropathy presenting with Alport syndrome-like findings: A case report. Ren H, Li L, Yu J, Wu S, Zhou S, Zheng Y, Sun W. Medicine (Baltimore) 98 e16256 (2019)
  119. Identification of a novel GLA mutation (F69 L) in a Japanese patient with late-onset Fabry disease. Umeda T, Hashimoto S, Noriyasu K, Takamura A, Fujisaki M, Eto Y. Hum Genome Var 2 15044 (2015)
  120. Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry. Moise A, Maeser S, Rawer S, Eggers F, Murphy M, Bornheim J, Przybylski M. J Am Soc Mass Spectrom 27 1071-1078 (2016)
  121. α-Galactosidase and Sucrose-Kinase Relationships in a Bi-functional AgaSK Enzyme Produced by the Human Gut Symbiont Ruminococcus gnavus E1. Lafond M, Tauzin AS, Bruel L, Laville E, Lombard V, Esque J, André I, Vidal N, Pompeo F, Quinson N, Perrier J, Fons M, Potocki-Veronese G, Giardina T. Front Microbiol 11 579521 (2020)
  122. Antibody Epitope of Human α-Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease. Kukacka Z, Iurascu M, Lupu L, Rusche H, Murphy M, Altamore L, Borri F, Maeser S, Papini AM, Hennermann J, Przybylski M. ChemMedChem 13 909-915 (2018)
  123. Clinical and genetic spectrum in Chinese families with Fabry disease: a single-centre case series. Chen X, Li H, Liao H, Zhan X, Zhong Z, Zhang Q, Liu L, Liang Y, Deng H, Fang X, Xue Y, Wu S, Liu Y. ESC Heart Fail 8 5436-5444 (2021)
  124. Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease. Zada M, Lo Q, Trivedi SJ, Harapoz M, Boyd AC, Devine K, Sadick N, Tchan MC, Thomas L. J Cardiovasc Dev Dis 9 11 (2022)
  125. Functional evaluation of a novel GLA causative mutation in Fabry disease. Li P, Zhang L, Xiong Q, Wang Z, Cui X, Zhou YA, Wang Y, Xiao H, Wu C. Mol Genet Genomic Med 7 e864 (2019)
  126. Inhibition of Mitochondrial Complex I Impairs Release of α-Galactosidase by Jurkat Cells. Lambert JRA, Howe SJ, Rahim AA, Burke DG, Heales SJR. Int J Mol Sci 20 E4349 (2019)
  127. Molecular basis for the affinity and specificity in the binding of five-membered iminocyclitols with glycosidases: an experimental and theoretical synergy. Shandilya A, Ganesan M, Parveen F, Ramesh NG, Jayaram B. Carbohydr Res 429 87-97 (2016)
  128. Multiple exo-glycosidases in human serum as detected with the substrate DNP-α-GalNAc. I. A new assay for lysosomal α-N-acetylgalactosaminidase. Albracht SPJ, Allon E, van Pelt J. BBA Clin 8 84-89 (2017)
  129. Supporting the Diagnosis of Fabry Disease Using a Natural Language Processing-Based Approach. Michalski AA, Lis K, Stankiewicz J, Kloska SM, Sycz A, Dudziński M, Muras-Szwedziak K, Nowicki M, Bazan-Socha S, Dabrowski MJ, Basak GW. J Clin Med 12 3599 (2023)
  130. The potential consequences of bidirectional promoter methylation on GLA and HNRNPH2 expression in Fabry disease phenotypes in a family of patients carrying a GLA deletion variant. Al-Obaide MA, Al-Obaidi II, Vasylyeva TL. Biomed Rep 17 71 (2022)
  131. Research Support, Non-U.S. Gov't UGA hopping: a sport for nephrologists too? Torra R, Oliveira JP, Ortiz A. Nephrol Dial Transplant 25 2391-2395 (2010)
  132. A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity. Mohamed FE, Al Sorkhy M, Ghattas MA, Al-Zaabi N, Al-Shamsi A, Almansoori TM, Al-Gazali L, Al-Dirbashi OY, Al-Jasmi F, Ali BR. J Mol Neurosci 70 45-55 (2020)
  133. Case Reports Endoscopic images in Fabry disease. Kouvaras SN. Ann Gastroenterol 25 354 (2012)
  134. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease. Zhou C, Huang J, Cui G, Zeng H, Wang DW, Zhou Q. BMC Med Genet 19 219 (2018)
  135. Optimizing human α-galactosidase for treatment of Fabry disease. Hallows WC, Skvorak K, Agard N, Kruse N, Zhang X, Zhu Y, Botham RC, Chng C, Shukla C, Lao J, Miller M, Sero A, Viduya J, Ismaili MHA, McCluskie K, Schiffmann R, Silverman AP, Shen JS, Huisman GW. Sci Rep 13 4748 (2023)
  136. Purification, Characterization, and Immobilization of a Novel Protease-Resistant α-Galactosidase from Oudemansiella radicata and Its Application in Degradation of Raffinose Family Oligosaccharides from Soymilk. Geng X, Lei J, Bau T, Guo D, Chang M, Feng C, Xu L, Cheng Y, Zuo N, Meng J. Foods 11 3091 (2022)
  137. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease. Yoshimitsu M, Higuchi K, Fan X, Takao S, Medin JA, Tei C, Takenaka T. Mol Biol Rep 38 3145-3152 (2011)
  138. Structural insight into the hydrolase and synthase activities of an alkaline α-galactosidase from Arabidopsis from complexes with substrate/product. Chuankhayan P, Lee RH, Guan HH, Lin CC, Chen NC, Huang YC, Yoshimura M, Nakagawa A, Chen CJ. Acta Crystallogr D Struct Biol 79 154-167 (2023)
  139. Structure based virtual screening of natural product molecules as glycosidase inhibitors. Moorthy NSHN, Brás NF, Ramos MJ, Fernandes PA. In Silico Pharmacol 9 56 (2021)
  140. GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease. Li P, Xi Y, Zhang Y, Samad A, Lan W, Wu Y, Zhao J, Chen G, Wu C, Xiong Q. Cells 13 437 (2024)
  141. In vitro characterization of cells derived from a patient with the GLA variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease. Breyer M, Grüner J, Klein A, Finke L, Klug K, Sauer M, Üçeyler N. Mol Genet Metab Rep 38 101029 (2024)
  142. A case of female Fabry disease revealed by renal biopsy. Aratani S, Yamakawa H, Suzuki S, Otsuka T, Sakai Y, Shimizu A, Tsuruoka S. CEN Case Rep 9 24-29 (2020)
  143. Agalsidase alfa for enzyme-replacement therapy in Fabry disease. Mehta A. Expert Rev Endocrinol Metab 5 641-652 (2010)
  144. Chemical and structural characterization of α-N-acetylgalactosaminidase I and II from starfish, asterina amurensis. Rashid MH, Sadik G, Alam AK, Tanaka T. BMC Biochem 18 9 (2017)
  145. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome. Fabian E, Schiller D, Toplak H, Brunner-Krainz M, Fazekas F, Schoefl R, Krejs GJ. Wien Klin Wochenschr 130 151-160 (2018)
  146. Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation. van Kuilenburg ABP, Hollak CEM, Travella A, Jacobs M, Gentilini LD, Leen R, der Vlugt KMMG, Stet FSB, Goorden SMI, van der Veen S, Criscuolo M, Papouchado M. Drugs R D 23 141-153 (2023)
  147. Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism? Aladağ N, Ali Barman H, Şipal A, Akbulut T, Özdemir M, Ceylaner S. Balkan J Med Genet 26 43-50 (2023)
  148. High-expression of Galactosidase alpha is correlated with poor prognosis and immune infiltration in low-grade glioma. Zhang Y, Li J, Yin X. J Cancer 14 646-656 (2023)
  149. Letter More on noncompaction in Fabry's disease. Martins E, Oliveira JP. Rev Port Cardiol 34 301-303 (2015)
  150. Case Reports Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report. Fu AY, Jin QZ, Sun YX. World J Clin Cases 10 1067-1076 (2022)
  151. [Molecular pathology and clinical manifestations of Fabry disease]. Rákóczi E, Görögh S, Grubits J, Erdos M, Garzuly F, Hahn K, Bencsik K, Vécsei L, Trinn C, Kristóf E, Mogyorósy G, Tóth B, Maródi L. Orv Hetil 148 1087-1094 (2007)
  152. [Neuro-otological manifestations in Fabry disease-a retrospective single center study]. Storck K, Stenzl A, Regenbogen C, Hofauer B, Knopf A. HNO 72 16-24 (2024)


Quick links